<DOC>
	<DOCNO>NCT02827357</DOCNO>
	<brief_summary>This chart review describe response systemic chemotherapy patient non-small cell lung cancer ( NSCLC ) harbour know somatic activate human epidermal growth factor receptor 2 ( HER2 ) mutation . The analysis data provide initial description response systemic chemotherapy patient NSCLC harbor activate HER2 mutation order inform design power future randomize controlled clinical trial HER2-directed therapy .</brief_summary>
	<brief_title>Responses Chemotherapy Patients With Non-small Cell Lung Cancer Harboring Known Somatic Activating HER2 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>patient advance nonsmallcell lung cancer know HER2 exon20 insertion treat chemotherapy and/or HER2targeted drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>